美敦力计划退出呼吸机生产，专注于患者监护和呼吸干预（PMRI）业务，并将履行现有的呼吸机合同。 Medtronic plans to exit ventilator production, focusing on Patient Monitoring and Respiratory Interventions (PMRI) businesses, and will honor existing ventilator contracts.
美敦力计划退出呼吸机生产，专注于有利可图的患者监测和呼吸干预（PMRI）业务。 Medtronic plans to exit ventilator production, focusing on profitable Patient Monitoring and Respiratory Interventions (PMRI) businesses. 不盈利的呼吸机产品线将被合并为一个名为急性护理和监测（ACM）的业务部门。 The unprofitable ventilator product line will be combined into one business unit called Acute Care and Monitoring (ACM). 该公司将履行现有的呼吸机合同，并期望其他制造商迎合市场。 The company will honor existing ventilator contracts and expects other manufacturers to cater to the market. 美敦力上调了 24 财年收入增长和每股收益指引，有机收入增长指引从 4.75% 提高到 4.75% 至 5% 的新范围，每股收益指引上调至 5.19 美元至 5.21 美元。 Medtronic raised its FY24 revenue growth and EPS guidance, with organic revenue growth guidance increased from 4.75% to a new range of 4.75% to 5%, and EPS guidance raised to $5.19 to $5.21.